Free tool
FAERS Monitor: Uloric
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021856 or its brand name (Uloric, Febuxostat). Reports on generic versions are filed under their own applications.
Reports
17,000
Serious
12,910
76% of reports
Hospitalization
7,336
Death reported
2,242
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea904
- acute kidney injury881
- nausea870
- rash812
- off label use772
- drug ineffective709
- gout700
- dyspnoea651
- fatigue628
- headache599
- anaemia598
- pneumonia569
- pyrexia565
- renal impairment541
- death538
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 73 |
| 2010 | 105 |
| 2011 | 196 |
| 2012 | 226 |
| 2013 | 294 |
| 2014 | 356 |
| 2015 | 2,414 |
| 2016 | 863 |
| 2017 | 867 |
| 2018 | 1,045 |
| 2019 | 1,142 |
| 2020 | 1,165 |
| 2021 | 1,431 |
| 2022 | 1,668 |
| 2023 | 1,474 |
| 2024 | 1,466 |
| 2025 | 1,325 |
| 2026 | 890 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,159 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| goutSignal | 700 | 50.2 | 46.6 | 32,403 |
| renal impairmentSignal | 541 | 8.0 | 7.4 | 3,305 |
| acute kidney injurySignal | 881 | 7.2 | 6.7 | 4,668 |
| anaemiaSignal | 598 | 3.9 | 3.6 | 1,288 |
| rashSignal | 812 | 2.3 | 2.2 | 612 |
| pneumoniaSignal | 569 | 2.2 | 2.0 | 366 |
| pyrexiaSignal | 565 | 2.0 | 1.9 | 295 |
| diarrhoea | 904 | 1.7 | 1.6 | 288 |
| dyspnoea | 651 | 1.4 | 1.3 | 84 |
| nausea | 870 | 1.4 | 1.3 | 86 |
| headache | 599 | 1.2 | 1.1 | 17 |
| off label use | 772 | 1.1 | 1.0 | 6 |
| fatigue | 628 | 1.0 | 0.9 | 0 |
| death | 538 | 0.8 | 0.7 | 37 |
| drug ineffective | 709 | 0.7 | 0.6 | 127 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.